Duisburg, Jan 21, 2022 - (JCN Newswire) - Mitsubishi Power Europe has signed a contract with Stockholm Exergi, the largest local district heating, cooling and electricity provider, to modernise the combined heat and power (CHP) plant - Kraftvarmeverk 1 (KVV1) at Vartaverket, Stockholm.
Although the plant was originally built in 1976 for fossil fuels, Mitsubishi Power Europe will modernize the boiler to handle sustainable recycled fuels like bio-oil. The large-scale renovation involves automating the plant's control system to a modern distributed control system (DCS) and installing new low NOx burners to reduce nitrogen dioxide emissions. The project also includes repairing pressure parts, installing selected sub-systems, and upgrading critical components. The CHP plant will be fully commissioned during the heating period in 2023 following two scheduled outages during the summer months for retrofitting.

Stockholm Exergi contributes to increasing resource efficiency by using renewable or recycled energy sources; 99 per cent of the district heating is generated from renewable or recycled fuels. In addition, increased urban migration and seasonal temperature variations with more intense cold spells led to a gap in the demand and supply of electricity early in the year.

The renovation project will enable higher energy efficiency and local renewable electricity production. Both are key to achieving positive climate impact, while ensuring affordability and reliability of power. Since bio-oil generates considerably lower NOx, the boiler conversion along with low NOx burners will substantially reduce emissions. The integrated DCS will enhance plant efficiency and reliability, improve system availability and enable remote monitoring, control and reporting.

Elvira Alberg, Project Manager at Stockholm Exergi says, "The modernisation of KVV1 resolves the challenges of reliability and availability through local capacity, use of biofuel and reduced emissions. The bio-oil used in KVV1 is obtained from the food and cosmetic industry residues. Retrofitting the existing firing system to handle bio-oil from heavy fuel oil will significantly extend the operational lifetime of the plant."

Andreas Rupp, Head of Sales Business Unit Service, Mitsubishi Power Europe says, "We are proud to partner with Stockholm Exergi to realize the city's goal of becoming fossil-free and climate-positive. Mitsubishi Power has served customers for over 100 years as a trusted partner in clean energy solutions with our advanced engineering expertise and modernization technologies. Our cutting-edge technical capabilities, patented systems and proven record enable us to offer unique solutions to our customers. The KVV1 retrofit project will help ensure sustainable and reliable clean energy production for the citizens of Stockholm."

"What makes this project unique is its complexity. The diverse combination of works, including installing a suitable biofuel firing system and modern automation systems, are addressed in a single project. As a trusted partner, Mitsubishi Power Europe has consistently come up with unique, wide-ranging solutions to address customer-specific requirements to move towards fossil-fuel-free goals. We look forward to delivering many more projects with our pioneering decarbonization technologies to our clients in the Scandinavian region," comments Carlos Gonzalez Peton, CEO of Mitsubishi Power Europe, Ltd.

MHI Group declared its commitment to carbon neutrality and has set a goal of achieving Net Zero CO2 emissions by 2040 under "MISSION NET ZERO". By making use of the portfolio of innovative technologies and services developed across all of company's business areas, Mitsubishi Power Europe will respond to customer needs, including decarbonization of existing infrastructure, and thereby support the world to reduce CO2 emissions.

For further information on Mitsubishi Power Europe's service, please visit https://power.mhi.com/regions/emea/services/boiler-service

About Mitsubishi Power in Europe, Middle East and Africa

Mitsubishi Power is a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI). Today, there are more than 1,000 employees across Europe, the Middle East and Africa, with centers of excellence in Germany, the United Kingdom, Saudi Arabia and the United Arab Emirates, in addition to customer support capabilities in countries across the region. Mitsubishi Power designs, manufactures and maintains equipment and systems that drive decarbonization and ensures the delivery of reliable power. Among its solutions are a wide range of gas turbines, including hydrogen-fuelled gas turbines and solid-oxide fuel cells (SOFCs), and an experienced services business with an extensive reach across the entire region. Committed to providing exemplary service and working with customers, Mitsubishi Power's TOMONI intelligent solutions leverages advanced analytics, adaptive control technology, artificial intelligence and machine learning to make power plants smarter, lowering emissions, increasing flexibility and supporting decarbonization.

For more information, please visit: https://power.mhi.com/regions/emea/

About Stockholm Exergi

We are Stockholm's energy company. All day, every day, we ensure that the fast-growing region of Stockholm has access to heating, cooling, electricity, and waste processing services. More than 800,000 people and over 400 hospitals, data centres, and businesses are connected to our district heating grid and our heat-and-power plants, ranging from Hogdalen south of Stockholm to Brista north of the city. By working together, we're powering the future of Stockholm - and have the potential of becoming the world's first climate-positive capital city.

PRESS CONTACT:
Claudia Wedemann
Mitsubishi Power Europe GmbH
Tel.: +49 203 8038 1368
Email: [email protected]


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comMitsubishi Power Europe has signed a contract with Stockholm Exergi, the largest local district heating, cooling and electricity provider, to modernise the combined heat and power (CHP) plant - Kraftvarmeverk 1 (KVV1) at Vartaverket, Stockholm.

Riyadh, Saudi Arabia, Jan 20, 2022 - (JCN Newswire) - Hitachi Rail announced today that it has signed a 72.5 million EUR contract with Princess Noura Bint Abdul Rahman University to operate and maintain the autonomous metro system in Riyadh, Saudi Arabia for the next three years.
The Princess Nourah Bint Abdul Rahman University is the largest women university in the world able to host 60,000 students that can travel within the huge campus area with the autonomous train. The electric powered trains provide a sustainable low carbon alternative to travelling by car.

The rail network consists of four elevated lines spanning 11.5 km that connects 14 stations. The 22 two-carriage automated metro trains have a capacity of 110 passengers and can travel to a maximum speed of 60 km/h.

The contract will see Hitachi operate the whole autonomous metro system, while maintaining the trains and infrastructure, including stations, mechanical and electrical systems and the depot and viaduct. Hitachi Rail completed the building of the autonomous railway in May 2011.

Hitachi is the largest autonomous manufacturer in the world with 30% market share. The company first autonomous metro started running in Copenhagen in 2002, and was followed by Line 5 in Milan, Brescia, Line C in Rome and successful system in Riyadh, Saudi Arabia and Taipei, Taiwan. Other projects are in progress in Honolulu - Hawaii, Thessaloniki - Greece, and Australia.

Edoardo La Ficara, Executive Officer, Operation Service & Maintenance Division, Hitachi Rail said, "We are proud to be confirmed as operator and maintainer of the Princess Noura University automated metro. This award is an important further milestone that consolidates our presence in the Middle East, one of the Operation, Service and Maintenance Division target markets. We're happy to be able to contribute with our customers to the development of mobility in the countries in which we operate, in terms of growth and sustainable systems".

Hitachi Rail has operated and maintained the Princess Noura Bint Abdul Rahman University since March 2018. Building up on the recent announcement on the maintenance of the new Spanish very high speed fleet, this new award is proof of Hitachi's continuous and positive collaboration with its customers enabling to operate and maintain the system in Riyadh for the next three years, powering sustainable connectivity.

About Hitachi Rail

Hitachi Rail is a fully integrated, global provider of rail solutions across rolling stock, signalling, service & maintenance, digital technology and turnkey solutions. With a presence in 38 countries across six continents and over 12,000 employees, our mission is to contribute to society through the continuous development of superior rail transport solutions. We are proud of our global achievements, from our world -famous 'bullet trains', to our signalling solutions and turnkey projects, state--of-the-art traffic management and digital solutions. Drawing on the wider Hitachi Group's market-leading technology and research-and-development capabilities, we strive for industry leading innovations and solutions that can deliver value for customers and sustainable railway systems that benefit wider society. For information about Hitachi Rail, visit www.hitachirail.com.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHitachi Rail announced today that it has signed a 72.5 million EUR contract with Princess Noura Bint Abdul Rahman University to operate and maintain the autonomous metro system in Riyadh, Saudi Arabia for the next three years.

TOKYO, Jan 20, 2022 - (JCN Newswire) - Honda Motor Co., Ltd. today announced that, in December 2021, the company invested in U.S. (California)-based Helm.ai to strengthen its software technology development in the areas of artificial intelligence (AI) and computer vision(1) technologies. Helm.ai has key strengths in the area of AI-based image recognition technologies advanced through unsupervised learning(2).

Helm.ai is an AI software startup established in November 2016, and Honda and Helm.ai have been working in collaboration since 2019 through Honda Xcelerator(3), a global open innovation program of Honda. Honda invested in Helm.ai to strengthen value creation in the efforts to make mobility products more intelligent and to generate greater achievements more quickly. The financing will further strengthen the relationship between the two companies and accelerate development of original solutions for Honda that combine Honda technologies and AI technologies of Helm.ai.

Honda will continue offering highly-competitive and highly-attractive products and services to its customers by establishing relationships through the Honda Xcelerator program with companies which have cutting-edge technologies in various areas.

(1) Technology to recognize specific elements from computer-based visual information and provide necessary information based on the results of such recognition.
(2) Unsupervised learning is one of the methods of machine learning, which supports AI. Unlike supervised learning through which AI learns the correct answers to derive from labeled input data, unsupervised learning lets AI learn without being provided with the correct answers and derives the patterns and unique characteristics of the unlabeled data on its own.
(3) Honda Xcelerator is a global open innovation program designed to facilitate collaboration between startups and Honda. The program is led by Honda Innovations Inc., a subsidiary of Honda Motor Co., Ltd. based in Silicon Valley in the U.S.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHonda Motor Co., Ltd. today announced that, in December 2021, the company invested in U.S. (California)-based Helm.ai to strengthen its software technology development in the areas of artificial intelligence (AI) and computer vision technologies.

TOKYO, Jan 20, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine. The pivotal study evaluated the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. versus chemotherapy (treatment of physician's choice of doxorubicin or paclitaxel) for patients with advanced endometrial carcinoma following at-least one prior platinum-based regimen in any setting.

The publication includes previously reported data that was first presented in an oral plenary session at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer.(1) Results showed that the LENVIMA plus KEYTRUDA combination demonstrated statistically significant improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. Objective response rate (ORR) data and additional detailed efficacy and safety data, including subgroup analyses, are also featured in the publication.

"While rates of endometrial carcinoma continue to rise globally, patients with advanced or recurrent disease have limited options available to them once the disease progresses following platinum-based chemotherapy," said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck Research Laboratories. "KEYNOTE-775/Study 309 is an important Phase 3 study that supported recent approvals of KEYTRUDA plus LENVIMA for certain types of advanced endometrial carcinoma in the U.S. and other countries around the world, where it became the first immunotherapy and tyrosine kinase inhibitor combination approved for these patients."

"The Phase 3 Study 309/KEYNOTE-775 trial demonstrates the ongoing commitment that Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. share in addressing the unmet needs of people living with difficult-to-treat cancers, including advanced endometrial carcinoma," said Corina Dutcus, M.D., Senior Vice President, Clinical Research, Oncology Business Group at Eisai Inc. "The publication of this study in the New England Journal of Medicine reflects the importance of our joint research in exploring the potential of the LENVIMA plus KEYTRUDA combination."

The publication contains results for the all-comer population, including the mismatch repair deficient (dMMR) patient population for which LENVIMA plus KEYTRUDA is not approved in the U.S.

Based on the results from the Phase 3 Study 309/KEYNOTE-775 trial, LENVIMA plus KEYTRUDA has been approved in the U.S. for patients with advanced endometrial carcinoma that is not microsatellite instability-high or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. LENVIMA plus KEYTRUDA is also approved in the European Union and Japan for certain patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in more than 10 different tumor types across more than 20 clinical trials.

(1) Eisai co., Ltd. Home page. "LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study". https://www.eisai.com/news/2021/news202116.html

Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
Investor Relations:
+81-(0) 70-8688-9685

Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Media Relations
Melissa Moody: +1-(215) 407-3536
Nikki Sullivan: +1-(718) 644-0730
Investor Relations
Peter Dannenbaum: +1- (908) 740-1037
Raychel Kruper: +1-(908) 740- 2107

For more information, visit https://www.eisai.com/news/2022/news202207.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine.

TOKYO, Jan 19, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been listed in the 2022 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's sixth inclusion on the list. Ranked 32nd, Eisai was the highest ranking company among global pharmaceutical companies.

The Global 100 evaluates the sustainability of approximately 6,900 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year. The Global 100 is based on up to 24 key performance indicators covering ESG initiatives, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai received high evaluation particularly on clean revenue and investment* and maintenance of work environment that ensures safety and health of employees.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.

*Sales revenue, R&D cost and investment for products such as medicines which are under equitable pricing strategies and included in the WHO Essentials Medicines Lists or used to treat any of in scope diseases, conditions and pathogens defined by the ATM Index Foundation.


Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that it has been listed in the 2022 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.

TOKYO, Jan 19, 2022 - (JCN Newswire) - As part of the next step into the energy management business, Honda is partnering with the V2X Suisse consortium to demonstrate the vital role of electric vehicles (EVs) and bi-directional charging technology in the future of energy management.

Honda will supply 50 Honda e electric vehicles to Switzerland's car sharing operator, Mobility. The Honda e units will be used as part of a car sharing fleet in a pioneering trial which uses the Honda e's bi-directional charging function to feed energy back to the grid when the vehicles are not in use for sharing. To allow bi-directional charging, Honda is also providing 35 Honda Power Manager units. These will deliver vehicle-to-grid (V2G) energy recovery capability for Mobility, at various urban and suburban sites across Switzerland.

The V2X Suisse trial includes the world's first mass-deployment of the COMBO-CCS (Combined Charging System) configuration with bi-directional functionality: currently Honda e is the only electric vehicle in the European market to allow both charging and discharging, as standard, for the European charging system CCS, making the Honda e the perfect vehicle to join the fleet.

Honda Power Manager is a bi-directional system that connects EVs to a power grid, enabling the collection and distribution of electricity between the two. This allows for intelligent balancing of the supply and demand of energy, including the better use of renewable sources and supports the stabilisation of the grid.

In this project, a total of 50 Honda e units will be allocated to 40 stations across Switzerland. A single Honda e can feed up to 20 kilowatts of power back into the grid when plugged into a bi-directional charging station. This not only regulates power to stabilise the grid during periods of high demand and minimise bottlenecks in the distribution of energy, but also reduces the need for expensive grid expansions as demand for EV charging increases.

Using a cloud-to-cloud IT platform developed by fellow consortium member sun2wheel, the Honda Power Manager units can manage the available power for each EV in 15 minute cycles to assess and regulate the flow of electricity. The scheme will enable Honda to verify the relationship between vehicle usage frequency and V2G operation, actual V2G operation time and frequency, and how this impacts on customer convenience.

Honda aims to create a sustainable society with zero environmental impact by connecting electrified mobility products and energy services, whilst contributing to the 'freedom of mobility' and 'expanding the use of renewable energy'. Not only the smart electric car, but innovations such as the bi-directional Honda Power Manager charging system will become increasingly important in a future carbon neutral society where both EVs and the use of renewable energy will become commonplace.

Through a real-world demonstration, Honda can conduct data collection and analysis of car sharing and V2G battery energy services, which will lead to the development of Honda's future energy services.

The actual demonstration of this project will start from September 2022, and will run until the end of 2023, includes consortium members Mobility, EVTEC, sun2wheel, tiko, Novatlantis and ETH Zurich, and is supported by the Swiss Federal Office of Energy.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comAs part of the next step into the energy management business, Honda is partnering with the V2X Suisse consortium to demonstrate the vital role of electric vehicles (EVs) and bi-directional charging technology in the future of energy management.

TOKYO, Jan 19, 2022 - (JCN Newswire) - Honda Motor Co., Ltd. today announced that, in December 2021, the company signed a joint development agreement in the area of Lithium-Metal secondary batteries(1) with SES Holdings Pte. Ltd.("SES"), a U.S. (Boston)-based EV battery research and development company.

Moreover, SES plans to list on the New York Stock Exchange (NYSE) via a special-purpose acquisition company (SPAC) transaction, and through the PIPE (private investment in public equity) offering by the SPAC, Honda plans to acquire approximately 2% of the shares of SES AI Corporation, the company to be listed on NYSE(2)(3).

The battery is a crucial component of battery electric vehicles (EV) and Honda, which is accelerating electrification of its products on a global basis, has been concurrently looking into several options for next-generation batteries, including the all-solid-state batteries Honda is developing independently. This joint development agreement with SES is part of the overall battery strategy of Honda.

From here onward, Honda and SES will pursue joint research for the realization of safe, high-durability and high-capacity next-generation EV batteries.

Comments by Shinji Aoyama, Managing Executive Officer in Charge of Electrification, Honda Motor Co., Ltd., "The battery is an essential component of EVs, and Honda has been concurrently looking into several options toward the realization of high-capacity, safe and low-cost next-generation batteries. Recognizing the advanced technologies of SES, Honda signed a joint development agreement with SES with the aim to establish a good relationship with SES and expeditiously generate substantial achievements through our joint research activities. Honda will continue to establish collaborative relationships with companies which have advanced technologies, as needed, to offer highly-competitive and attractive EVs to our customers."

(1) Batteries with Lithium-Metal anode, which are expected to realize higher energy density than Lithium-ion batteries (which usually use carbon-based materials for the anode).
(2) On October 22, 2021, Honda signed a PIPE subscription agreement with Ivanhoe Capital Acquisition Corp. ("Ivanhoe"), a special-purpose acquisition company (SPAC) listed on the NYSE, pursuant to which Honda is scheduled to acquire shares of Ivanhoe on the day of the merger between SES and a wholly-owned subsidiary of Ivanhoe, with SES the surviving entity ("the merger"), prior to the completion of the merger. Ivanhoe, which will wholly own SES, plans to change its name to SES AI Corporation prior to the completion of the merger. Fulfillment of all prerequisites for the execution of the merger, including approval of SES and Ivanhoe shareholders, is a prerequisite for the stock purchase by Honda.
(3) The shareholding percentage above is based on the assumption that the shareholders of Ivanhoe will not exercise their redemption rights.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHonda Motor Co., Ltd. today announced that, in December 2021, the company signed a joint development agreement in the area of Lithium-Metal secondary batteries(1) with SES Holdings Pte. Ltd.(SES), a U.S. (Boston)-based EV battery research and development company.

TOKYO, Jan 19, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study). The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).

People who have genetic mutations of DIAD are known to develop Alzheimer's disease (AD) and will likely develop symptoms at around the same age their affected parents did, often in their 50s, 40s or even 30s. The major AD pathologies are amyloid plaque that consists of amyloid beta (Abeta) aggregates; neurofibrillary tangles; and intraneuronal aggregates of tau, all of which are believed to spread throughout the brain.

The purpose of the Tau NexGen study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational therapies in pre-symptomatic or symptomatic participants who have an AD-causing gene mutation. In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study. With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of AD, the Tau NexGen clinical trial leaders selected Eisai's investigational anti-Abeta protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.

Eisai positions neurology as a key therapeutic area, and it will continue to create innovation in the development of novel medicines based on cutting-edge neurology research as it seeks to contribute further to improving the benefits of affected individuals and their families in diseases with high unmet needs, such as dementia including AD.

About Dominantly Inherited Alzheimer Network (DIAN)

The DIAN is an international research effort focused on dominantly inherited Alzheimer's disease. Dominantly Inherited Alzheimer's disease (DIAD) is a rare form of Alzheimer's disease (AD) that causes memory loss and dementia in individuals -- typically while they are in their 30s to 50s. The disease affects less than 1% of the total population of people with AD. The aim of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is to find solutions to treat or prevent this disease and, potentially, all forms of Alzheimer's. The DIAN-TU is an international public-private partnership dedicated to designing and managing interventional therapeutic trials for individuals with and at risk of DIAD.

About Tau NexGen study

The purpose of the Tau NexGen study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational therapies in people who have an AD-causing gene mutation. In the Tau NexGen study, symptomatic participants will be administered anti-amyloid beta (Abeta) protofibril antibody lecanemab for six months before being randomly assigned to also receive the anti-tau drug or a placebo. Since amyloid plaques accumulate before tau tangles in AD, this study design allows the researchers to assess whether amyloid removal clears the way for the anti-tau drug to function most effectively. Pre-symptomatic participants will be randomly assigned to receive the anti-tau drug or a placebo for a year before beginning lecanemab administration. By staggering the drugs in this way, the researchers will be able to evaluate the effects of the anti-tau drug alone before assessing the effects of the two drugs together. If the primary and secondary endpoints are positive in the analysis two years after the start of study, the study will be extended for another two years to assess whether the drug slows cognitive decline and has further effects on tau pathology.

About E2814

An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease modifying agent for tauopathies including sporadic AD. Phase I clinical studies are underway. E2814 was discovered as part of the research collaboration between Eisai and University College London. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals.

About Lecanemab (BAN2401)

Lecanemab is an investigational humanized monoclonal antibody for AD that is the result of a strategic research alliance between Eisai and BioArctic. Lecanemab selectively binds to neutralize and eliminate soluble, toxic Abeta aggregates (protofibrils) that are thought to contribute to the neurodegenerative process.

in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. With regard to the results from pre-specified analysis at 18 months of treatment, Study 201 demonstrated reduction of brain Abeta accumulation (P<0.0001) and slowing of disease progression measured by ADCOMS* (P<0.05) in early AD subjects. The study did not achieve its primary outcome measure** at 12 months of treatment. The Study 201 open-label extension was initiated after completion of the Core period and a Gap period off treatment (average of 24 months) to evaluate safety and efficacy, and is underway.

Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab and the parties amended that agreement in October 2017. Currently, lecanemab is being studied in a pivotal Phase III clinical study in symptomatic early AD (Clarity AD), following the outcome of the Phase II clinical study ( Study 201). In July 2020 the Phase III clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, was initiated. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S., funded by the National Institute on Aging, part of the National Institutes of Health, and Eisai.

In September 2021, a rolling submission to the FDA of a Biologics License Application (BLA) for the treatment of early AD under the accelerated approval pathway was initiated. Lecanemab was granted Breakthrough Therapy designation in June 2021, a U.S. Food and Drug Administration (FDA) program intended to expedite the development and review of medicines for serious or life-threatening conditions.

* Developed by Eisai, ADCOMS (AD Composite Score) combines items from the ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale), CDR (Clinical Dementia Rating) and the MMSE (Mini- Mental State Examination) scales to enable a sensitive detection of changes in clinical functions of early AD symptoms and changes in memory.
** An 80% or higher estimated probability of demonstrating 25% or greater slowing in clinical decline at 12 months treatment measured by ADCOMS from baseline compared to placebo

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc (U.S.) Libby Holman 201-753-1945
[email protected]

Investor Contact:
Eisai Co., Ltd.
Investor Relations Department
TEL: +81-(0)70-8688-9685


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comE isai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study).

Toyota City, Japan, Jan 18, 2022 - (JCN Newswire) - At Toyota, we have made repeated adjustments to our production plans due to a parts shortage resulting from the spread of COVID-19, causing various inconveniences to our customers and all parties concerned. We would like to express our gratitude to everyone involved for their immense support in helping us maintain production.
Our global production plan in February 2022 is expected to be around 700,000 units. Current demand is very strong, therefore we were aiming for a high February production plan. However, due to the impact of the continuing demand for semiconductors across all industries, we have adjusted our production plan by around 150,000 units globally.

As a result of the revision, the full-year production forecast for the fiscal year ending March 31, 2022 is expected to be lower than the previous forecast of 9 million units.

With regards to the shortage of semiconductor-related parts, we will continue to examine the situation and consult with all companies involved in considering the use of substitutes where possible in anticipation of a continuing shortage.

We will also continue to work with our suppliers in strengthening the supply chain and make every effort to deliver vehicles to our customers as soon as possible.

The following is the schedule for the suspension of domestic operations in February due to the plan revisions. We would like to offer our sincerest apologies to our customers and suppliers for the various inconveniences these adjustments may cause.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comAt Toyota, we have made repeated adjustments to our production plans due to a parts shortage resulting from the spread of COVID-19, causing various inconveniences to our customers and all parties concerned.

TOKYO, Jan 18, 2022 - (JCN Newswire) - The Nippon Foundation, Mitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries Group, and Shin Nihonkai Ferry Co., Ltd., (Osaka, Japan; Yasuo Iritani, Chairman) have successfully completed a demonstration test of the world's first fully autonomous ship navigation systems on a large car ferry, conducted on the Iyonada Sea from Shinmoji, Kitakyushuu City, on January 17.
This demonstration was part of MEGURI 2040, a project promoting the development of fully autonomous vessels supported by The Nippon Foundation. This test demonstrated the world's first fully autonomous navigation system, on a 222-meter ferry, with autonomous port berthing and unberthing using turning and reversing movements and high-speed navigation of up to 26 knots. Other new technologies included in the advanced fully autonomous operation system include sensors to detect other ships using infrared cameras, a remote engine monitoring system, and a sophisticated cyber security system. These advances in fully autonomous ship navigation are seen as a significant step toward safer and more efficient coastal shipping.

Research and development of fully autonomous ship navigation is intended to address maritime issues including crew shortages and accident prevention. This is also expected to become a "future industry" through which Japan can demonstrate to the world its advanced technologies in areas including ICT, AI, and image analysis technology.

The Nippon Foundation launched the MEGURI 2040 fully autonomous ship navigation project in February 2020 through support for five consortia, which will all be conducting demonstration tests to verify their fully autonomous navigation system concepts from January to March 2022.

Fully autonomous ship project (Smart Coastal Ferry)

Today's successful demonstration test was of the fully autonomous Smart Coastal Ferry project. The newly built SOLEIL ferry began navigating with an onboard crew on July 1, 2021, compiling data for the development of a fully autonomous ship navigation system. Mitsubishi Shipbuilding Co., Ltd., which has experience in developing navigation support systems that realize automation and crew labor savings, is responsible for the integration of the entire system, and Shin Nihonkai Ferry Co., Ltd. is in charge of setting the vessel's system requirements and conducting the demonstration test. These developments will help resolve issues in coastal shipping including improved safety, crew labor savings, and cost reductions.

Demonstration test and development highlights

The demonstration test of the world's first fully autonomous ship navigation systems of the 222-meter smart vessel was conducted on a 240-km route from Shinmoji (Northern Kyushu) to Iyonada, which takes approximately 7 hours, at a maximum speed of 26 knots (approximately 50 km/hour). The test vessel was equipped with a high-precision sensor image analysis system with infrared cameras that can detect other ships even in darkness, a SUPER BRIDGE-X automated ship navigation system that includes an automated avoidance function, and an advanced automated port berthing/unberthing operation system that can perform turning and reversing movements that are even difficult for manned vessels.

One of the biggest issues of a fully automated vessel is fault prediction, and enhanced engine monitoring technologies that monitor motor conditions are being developed and tested as well.
The project is also developing various other technologies essential to the promotion of fully autonomous navigation, including platforms for advanced data security to protect the navigation data used for onshore monitoring and support.

Mitsuyuki Unno, Executive Director, The Nippon Foundation
This was the world's first fully autonomous ship navigation of a large vessel of over 200 meters in length with a maximum running speed of 26 knots, and I hope this will lead to further development toward practical use. There are still many issues to be resolved, however, and I believe today's results will be a guide toward the creation of international rules for fully autonomous vessels.

Naoki Ueda, Executive Vice President, Mitsubishi Shipbuilding Co., Ltd
This demonstration test greatly accelerated the development of fully autonomous ship navigation systems using many advanced technologies including artificial intelligence. We will continue to develop technologies using the valuable knowledge gained to achieve safety and high quality service for passenger ferries, which play an important role in supporting marine transportation in the island nation of Japan.

Masami Sasaki, Executive Director, Shin Nihonkai Ferry Co., Ltd.
We are honored to be involved in the development of a fully autonomous ship navigation system that represents the future of Japan's shipping industry.

As a passenger ferry company, we have high expectations for the social application and widespread use of fully autonomous operation as one of the solutions to issues including human error and crew labor savings.

About MHI Group

Mitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on www.spectra.mhi.com.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comThe Nippon Foundation, Mitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries Group, and Shin Nihonkai Ferry Co., Ltd., (Osaka, Japan; Yasuo Iritani, Chairman) have successfully completed a demonstration test of the world's first fully autonomous ship navigation systems on a large car ferry, conducted on the Iyonada Sea from Shinmoji, Kitakyushuu City, on January 17.

TOKYO, Jan 18, 2022 - (JCN Newswire) - Honda announced plans to begin sales of an all-new EU32i portable generator equipped with a newly designed dedicated engine (maximum output: 3.2kVA). Sales will begin in the European region in March of this year, followed by the expansion of sales to other regions around the world.
With the diversification of generator use, including as a power source for various outdoor and recreational activities, and backup power supply during emergency situations such as a disaster, the needs for high-output yet compact, lightweight and portable generators have been increasing. To fulfill such needs, EU32i, an all-new generator equipped with a newly-developed dedicated GX130 engine with a sine wave inverter, which features both 3kVA-class high output and lightweight, compact and highly portable packaging. Featuring Honda?s original sine wave inverter technology, the EU32i can provide a stable supply of high-quality electrical output with smooth waveform, which even makes EU32i compatible with precision instruments that require high-quality electricity.

For the exterior design, black-base coloring was adopted for the first time among all Honda generators. While generating a sharp image by accentuating shading, the design with rounded corners was adopted to mitigate possible damage and the risk of bumping into people or other objects while being carried.

Moreover, utilizing a dedicated app on a smartphone and Bluetooth communication, the user can check the status of the EU32i generator, including the remaining fuel level and operating time, and remotely control the generator including turning off the engine, which increases user friendliness.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHonda announced plans to begin sales of an all-new EU32i portable generator equipped with a newly designed dedicated engine (maximum output: 3.2kVA).

TOKYO, Jan 17, 2022 - (JCN Newswire) - The TOYOTA GAZOO Racing World Rally Team will begin a bold new era in the FIA World Rally Championship when the 2022 season begins and the GR YARIS Rally1 makes its debut on the legendary Rallye Monte-Carlo from January 20-23.
The GR YARIS Rally1 is the successor to the all-conquering Yaris WRC, which claimed a clean sweep of the manufacturers', drivers' and co-drivers' in the 2021 season that concluded just eight weeks ago at Monza in Italy. Now, the roads of the French Alps will play host to the first event for the revolutionary Rally1 cars, which take over from the World Rally Cars that have formed the highest category of the WRC for the past quarter of a century.

Rally1 cars feature several significant changes compared to their predecessors, headlined by the arrival of hybrid technology to the highest level of rallying for the first time. The hybrid unit in each car comprises of a 3.9kWh battery and a motor-generator unit (MGU) delivering an additional 100 kW (134 PS) under acceleration.

In the GR YARIS Rally1, this is combined with the proven 1.6-litre turbocharged engine from the Yaris WRC to provide the drivers with over 500 PS. The engine will run on a 100 per cent sustainable fuel: The first of its kind to be used in an FIA world championship.

The GR YARIS Rally1 is built around a dedicated spaceframe chassis offering increased safety protection for drivers and co-drivers. Other transformations required by the regulations include less complex aerodynamics, a return to a mechanical gearshift and the removal of the active centre differential. These changes will increase the focus on the skills of the drivers, who will also need to adapt to the demands around regenerating and deploying the hybrid energy on the stages, while working with their engineers to optimise the performance and drivability within these new parameters.

Since it ran for the first time last spring, the GR YARIS Rally1 has undergone a thorough testing programme which for the last few weeks has been focused on the particular demands of Rallye Monte-Carlo. The event is famed for its changeable conditions, which can vary from dry asphalt to snow and ice, and could provide an especially challenging start for the drivers in their new cars.

When the rally begins on Thursday night, the GR YARIS Rally1 of reigning champion Sebastien Ogier will be the first of the new generation of cars to start a competitive stage. The eight-time world champion, who has also won Rallye Monte-Carlo a record eight times, is embarking on a partial schedule of events this season along with a new co-driver, Benjamin Veillas. Leading TOYOTA GAZOO Racing's effort over the full season will be Elfyn Evans and his co-driver Scott Martin, who finished second in the 2021 standings, and Kalle Rovanpera and his co-driver Jonne Halttunen, who came fourth overall last season.

A total of four GR YARIS Rally1 cars will be present on every round with Takamoto Katsuta and co-driver Aaron Johnston contesting the full season for a newly-created team, TOYOTA GAZOO Racing World Rally Team Next Generation.

The crews today begin three days of reconnaissance of the stages, 85 per cent of which are new compared to 2021. For the 90th edition of the rally, the service park moves to Monaco itself from Gap. After a shakedown on Thursday morning, the rally will begin in the evening from the iconic Casino Square ahead of an opening pair of night stages - the second includes a return to the classic Col de Turini, to be passed in darkness for the first time since 2013.

Friday is the longest day of the rally and consists of three stages to be run twice with no mid-day service, only a tyre-fitting zone in Puget-Theniers. The task is similar on Saturday, which takes place further to the west: Three stages will be run in the morning, two of which will be repeated in the afternoon after a tyre-fitting zone in Digne-les-Bains. The rally's final day on Sunday is made up of two stages run twice - the latter stage finishing in Entrevaux is the only one that is identical to last year.

For more information visit https://toyotagazooracing.com/wrc/release/2022/rd01-preview/.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comThe TOYOTA GAZOO Racing World Rally Team will begin a bold new era in the FIA World Rally Championship when the 2022 season begins and the GR YARIS Rally1 makes its debut on the legendary Rallye Monte-Carlo from January 20-23.